- Home
- ZENV vs CABA Comparison
ZENV vs CABA Comparison
Compare ZENV & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- CABA
- Stock Information
- Founded
- ZENV 2005
- CABA 2017
- Country
- ZENV Brazil
- CABA United States
- Employees
- ZENV N/A
- CABA N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZENV Technology
- CABA Health Care
- Exchange
- ZENV Nasdaq
- CABA Nasdaq
- Market Cap
- ZENV 146.3M
- CABA 118.8M
- IPO Year
- ZENV 2021
- CABA 2019
- Fundamental
- Price
- ZENV $2.15
- CABA $2.06
- Analyst Decision
- ZENV
- CABA Strong Buy
- Analyst Count
- ZENV 0
- CABA 8
- Target Price
- ZENV N/A
- CABA $26.13
- AVG Volume (30 Days)
- ZENV 121.2K
- CABA 1.3M
- Earning Date
- ZENV 11-18-2024
- CABA 03-20-2025
- Dividend Yield
- ZENV N/A
- CABA N/A
- EPS Growth
- ZENV N/A
- CABA N/A
- EPS
- ZENV N/A
- CABA N/A
- Revenue
- ZENV $173,594,726.00
- CABA N/A
- Revenue This Year
- ZENV $28.66
- CABA N/A
- Revenue Next Year
- ZENV $2.98
- CABA N/A
- P/E Ratio
- ZENV N/A
- CABA N/A
- Revenue Growth
- ZENV 23.49
- CABA N/A
- 52 Week Low
- ZENV $1.12
- CABA $1.76
- 52 Week High
- ZENV $3.88
- CABA $24.85
- Technical
- Relative Strength Index (RSI)
- ZENV 40.78
- CABA 38.28
- Support Level
- ZENV $1.87
- CABA $2.03
- Resistance Level
- ZENV $2.45
- CABA $2.90
- Average True Range (ATR)
- ZENV 0.21
- CABA 0.24
- MACD
- ZENV -0.05
- CABA -0.04
- Stochastic Oscillator
- ZENV 37.53
- CABA 4.00
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.